WO2004017923A3 - Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix - Google Patents

Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix Download PDF

Info

Publication number
WO2004017923A3
WO2004017923A3 PCT/US2003/026612 US0326612W WO2004017923A3 WO 2004017923 A3 WO2004017923 A3 WO 2004017923A3 US 0326612 W US0326612 W US 0326612W WO 2004017923 A3 WO2004017923 A3 WO 2004017923A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
antibodies
compositions
antagonist anti
inhibitory
Prior art date
Application number
PCT/US2003/026612
Other languages
French (fr)
Other versions
WO2004017923A2 (en
Inventor
Justin Wong
Jill Winter
Guita Lalehzadeh
Robert Warne
Original Assignee
Chiron Corp
Justin Wong
Jill Winter
Guita Lalehzadeh
Robert Warne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Justin Wong, Jill Winter, Guita Lalehzadeh, Robert Warne filed Critical Chiron Corp
Priority to EP03749129A priority Critical patent/EP1576010A4/en
Priority to US10/525,535 priority patent/US20090252738A1/en
Priority to JP2004531195A priority patent/JP2005536220A/en
Priority to AU2003268180A priority patent/AU2003268180A1/en
Priority to CA002496572A priority patent/CA2496572A1/en
Publication of WO2004017923A2 publication Critical patent/WO2004017923A2/en
Publication of WO2004017923A3 publication Critical patent/WO2004017923A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Abstract

Compositions and methods useful in inhibiting proliferation of CA IX + preneoplastic or neoplastic cells in a mammal are provided. The compositions are antagonist anti-CA IX antibodies and other inhibitory agents that target carbonic anhydrase activity of CA IX on these cells. The antagonist anti-CA IX antibodies or antigen-binding fragments thereof are specifically reactive with an inhibitory epitope of CA IX or biologically active variant thereof. Formation of an antibody-antigen complex between the antagonist anti-CA IX antibodies or antigen-binding fragments thereof and the respective inhibitory epitopes results in inhibition of carbonic anhydrase activity of CA IX or biologically active variant thereof. Other small molecule agents that inhibit carbonic anhydrase activity of CA IX or biologically active variant thereof and screening assays for identifying such agents are also provided. The antagonist anti-CA IX antibodies, antigen-binding fragments thereof, and other CA IX inhibitory agents identified herein are useful in the treatment of cancers characterized by the expression of the CA IX tumor-associated antigen.
PCT/US2003/026612 2002-08-23 2003-08-25 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix WO2004017923A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP03749129A EP1576010A4 (en) 2002-08-23 2003-08-25 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
US10/525,535 US20090252738A1 (en) 2002-08-23 2003-08-25 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
JP2004531195A JP2005536220A (en) 2002-08-23 2003-08-25 Therapeutic compositions and methods for cancer characterized by the expression of tumor associated antigen MN / CAIX
AU2003268180A AU2003268180A1 (en) 2002-08-23 2003-08-25 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
CA002496572A CA2496572A1 (en) 2002-08-23 2003-08-25 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40557702P 2002-08-23 2002-08-23
US60/405,577 2002-08-23
US64693403A 2003-08-22 2003-08-22
US10/646,934 2003-08-22

Publications (2)

Publication Number Publication Date
WO2004017923A2 WO2004017923A2 (en) 2004-03-04
WO2004017923A3 true WO2004017923A3 (en) 2005-07-14

Family

ID=31949897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/026612 WO2004017923A2 (en) 2002-08-23 2003-08-25 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix

Country Status (5)

Country Link
EP (1) EP1576010A4 (en)
JP (1) JP2005536220A (en)
AU (1) AU2003268180A1 (en)
CA (1) CA2496572A1 (en)
WO (1) WO2004017923A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4488351B2 (en) 2002-02-21 2010-06-23 インスティトゥート オブ ヴァイロロジー Soluble carbonic anhydrase IX (s-CAIX), assay to detect s-CAIX, co-expression of CAIX and HER-2 / neu / c-erbB-2, CAIX specific monoclonal for non-immunodominant epitopes antibody
US7833734B2 (en) 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
DOP2006000277A (en) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp ANTI MN ANTIBODIES AND METHODS FOR USE
WO2008091798A2 (en) * 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
EP2234608A2 (en) * 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EP3966253A4 (en) * 2019-05-06 2023-02-22 Navi Bio-Therapeutics, Inc. Anti-carbonic anhydrase ix antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024913A2 (en) * 1998-10-23 2000-05-04 Bayer Corporation Mn gene and protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1576010A4 *

Also Published As

Publication number Publication date
EP1576010A4 (en) 2006-12-27
WO2004017923A2 (en) 2004-03-04
AU2003268180A8 (en) 2004-03-11
EP1576010A2 (en) 2005-09-21
JP2005536220A (en) 2005-12-02
AU2003268180A1 (en) 2004-03-11
CA2496572A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
JP2009502139A5 (en)
WO2003100008A3 (en) Neutralizing human anti-igfr antibody
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
HK1134303A1 (en) Fab fragment libraries and methods for their use fab
RU2008106760A (en) ANTIBODIES AGAINST CD26 AND WAYS OF THEIR APPLICATION
HK1076128A1 (en) Humanized collagen antibodies and related methods
RU2010136940A (en) ANTIBODIES AGAINST ALPHA5-BETA1 AND THEIR APPLICATION
IN2009KN02655A (en)
HK1095334A1 (en) Methods for forming humanised antibodies by random mutagenesis
JP2009521913A5 (en)
DE69829891D1 (en) Anti-VEGF antibody
EP2186884A3 (en) HCV-anti-core monoclonal antibody
AU2002951409A0 (en) Methods for regulating cancer
WO2004022717A3 (en) Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
JP2007526908A5 (en)
WO2004017923A3 (en) Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
WO2002094853A3 (en) Antibodies specific for poly(ethylene glycol)
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2004050849A3 (en) Recombinant immunotoxin and use in treating tumors
WO2003072727A3 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
JP2006521388A5 (en)
WO2004113388A3 (en) Anti alpha - folate - receptor - tetramer antibodies
WO2003106478A3 (en) ANTIBODIES THAT BIND alphaE INTEGRIN
WO2002094194A3 (en) Compositions and methods for inhibiting metastasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004531195

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2496572

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003749129

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003749129

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10525535

Country of ref document: US